Monoclonal antibodies used as prophylactic, therapeutic and diagnostic agents

References

• Keenan, A.M., Harbert, J.C., Larson, S.M. Monoclonal antibodies in nuclear medicine. J. Nucl. Med. 1985, 26, 531–537.
   PubMed Web of Science ®Google Scholar
• McCall, D., Stock, D., Achey, P. Antigen-antibody reactions in host defense and in serology. In 11th Hour Introduction to Microbiology (pp. 204–205). Massachusetts: Blackwell Science Inc., 2001.
   Google Scholar
• Cowden, J., Parker, S.K. Monoclonal antibodies: production, uses and side effects. Pediatr. Infect. Dis. J. 2006, 25, 553–555.
   PubMedGoogle Scholar
• Spiegel, H.E. Advances in Clinical Chemistry. Vol. 27. Academic Press, Inc., Utah, USA. 1989.
   Google Scholar
• Thomas, J.A., Thomas, M.J. New biologics: their development, safety, and efficacy. In Thomas, J.A., Myers, L.A., eds. Biotechnology and Safety Assessment (pp. 15–20). New York: Raven Press, 1993.
   Google Scholar
• Hickman-Davis, J.M., Davis, I.C. Transgenic mice. Paediatr. Respir. Rev. 2006, 7, 49–53.
   PubMed Web of Science ®Google Scholar
• Marks, C., Marks, J.D. Phage libraries—a new route to clinically useful antibodies. N. Engl. J. Med. 1996, 335, 730–733.
   PubMed Web of Science ®Google Scholar
• Gillies, S.D., Dorai, H., Wesolowski, J., et al. Expression of human anti-tetanus toxoid antibody in transfected murine myeloma cells. Nat. Biotechnol. 1989, 7, 799–804.
   Google Scholar
• Hale, G., Jacobs, P., Wood, L., et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000, 26, 69–76.
   PubMed Web of Science ®Google Scholar
• Beniaminovitz, A., Itescu, S., Lietz, K., et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N. Engl. J. Med. 2000, 342, 613–619.
   PubMed Web of Science ®Google Scholar
• Monoclonal antibodies. Making treatment decisions. http://www.cancer.org/docroot/ETO/content/ETO_1_4X_Monoclonal_Antibody_Therapy_Passive_Immunotherapy.asp. Updated October 27, 2009. (accessed November 18, 2009).
   Google Scholar
• Bishop, M.R. Monoclonal antibodies. http://www.meds.com/immunotherapy/monoclonal_antibodies.html (accessed November 20, 2009.).
   Google Scholar
• Bross, P.F., Beitz, J., Chen, G., et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 2001, 7, 1490–1496.
   PubMed Web of Science ®Google Scholar
• Vallera, D.A. Gene therapy with immunotoxins. Methods Mol. Biol. 2001, 166, 235–246.
   PubMedGoogle Scholar
• Frankel, A.E., Neville, D.M., Bugge, T.A., Kreitman, R.J., Leppla, S.H. Immunotoxin therapy of hematologic malignancies. Semin. Oncol. 2003, 30, 545–557.
   PubMed Web of Science ®Google Scholar
• Eyzaguirre, E., Haque, A.K. Application of immunohistochemistry to infections. Arch. Pathol. Lab. Med. 2008, 132, 424–431.
   PubMed Web of Science ®Google Scholar
• Larson, S.M. Lymphoma, melanoma, colon cancer: diagnosis and treatment with radiolabeled monoclonal antibodies. The 1986 Eugene P. Pendergrass New Horizons Lecture. Radiology. 1987, 165, 297–304.
   PubMed Web of Science ®Google Scholar
• Rubello, D., Rampin, L., Banti, E., et al. Diagnosis of infected total knee arthroplasty with anti-granulocyte scintigraphy: the importance of a dual-time acquisition protocol. Nucl. Med. Commun. 2008, 29, 331–335.
   PubMedGoogle Scholar
• Basu, S., Zhuang, H., Torigian, D.A., Rosenbaum, J., Chen, W., Alavi, A. Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin. Nucl. Med. 2009, 39, 124–145.
   PubMed Web of Science ®Google Scholar
• Love, C., Palestro, C.J. Radionuclide imaging of infection. J. Nucl. Med. Technol. 2004, 32, 47–57; quiz 58.
   PubMedGoogle Scholar
• Förster, M., Conradi, S., Müller, D., Kluge, R., Sabri, O. Heart abscess revealed by nuclear medicine imaging. Eur. J. Nucl. Med. Mol. Imaging. 2005, 32, 249.
   PubMedGoogle Scholar
• Larson, S.M. Radioimmunology. Imaging and therapy. Cancer. 1991, 67, 1253–1260.
   PubMed Web of Science ®Google Scholar
• Elgert, K.D. Immunology: Understanding the Immune System. John Wiley and Sons, Inc., New Jersey, USA. 2009; Edition 2.
   Google Scholar
• Gama Sosa, M.A., De Gasperi, R., Elder, G.A. Animal transgenesis: an overview. Brain Struct. Funct. 2010, In Press.
   Google Scholar
• Prete, M., Perosa, F., Favoino, E., Dammacco, F. Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease. Clin. Exp. Med. 2005, 5, 141–160.
   PubMedGoogle Scholar
• Huang, S.-H., Jong, A. Expression and preparation of fusion proteins from recombinant λgt11 phages. In Rapley, R., ed. The Nucleic Acid Protocols Handbook (pp. 367–371). New Jersey: Humana Press Inc., 2000.
   Google Scholar
• Fleischmann, R., Shealy, D. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. Mol. Interv. 2003, 3, 310–318.
   PubMedGoogle Scholar
• Understanding monoclonal antibodies. Drug. Ther. Bull. 2007, 45, 55–56.
   PubMedGoogle Scholar
• Zhang, Z., Zhong, R., Jiang, J., et al. Prevention of heart allograft and kidney xenograft rejection by monoclonal antibody to CD45RB. Transplant. Proc. 1997, 29, 1253.
   PubMed Web of Science ®Google Scholar
• Cogny-Van Weydevelt, F., Prud’,Homme, L., Boucher, A., Dandavino, R. Risk-benefit of OKT3 prophylaxis in immunologic high-risk cadaver kidney transplant recipients. Transplant. Proc. 1997, 29, 32S–34S.
   PubMedGoogle Scholar
• Bäuerle, T., Hilbig, H., Bartling, S., et al. Bevacizumab inhibits breast cancer-induced osteolysis, surrounding soft tissue metastasis, and angiogenesis in rats as visualized by VCT and MRI. Neoplasia 2008, 10, 511–520.
   PubMed Web of Science ®Google Scholar
• Hauser, S.L., Waubant, E., Arnold, D.L., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358, 676–688.
   PubMed Web of Science ®Google Scholar
• Punt, C.J., Nagy, A., Douillard, J.Y., et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study. Lancet 2002, 360, 671–677.
   PubMed Web of Science ®Google Scholar
• Bar-Or, A., Calabresi, P.A., Arnold, D., et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann. Neurol. 2008, 63, 395–400.
   PubMed Web of Science ®Google Scholar
• Reid, R.F., Sindelar, R.D. Pharmaceutical biotechnology—from nucleic acids to personalized medicine. In Lemke, T.L., Williams, D.A., Roche, V.F., Zito, S.W., eds. Foye’s Principles of Medicinal Chemistry (pp. 115–174). Maryland and Pennsylvania: Lippincott Williams & Wilkins, 2008.
   Google Scholar
• Iwakura, Y., Ishigame, H. The IL-23/IL-17 axis in inflammation. J. Clin. Invest. 2006, 116, 1218–1222.
   PubMed Web of Science ®Google Scholar
• Abdelnoor, A.M. Patented small molecules against psoriasis. Expert Opin. Ther. Pat. 2009, 19, 1057–1071.
   PubMed Web of Science ®Google Scholar
• Driver, L.C., Oertel, M.D. Synagis: an anti-RSV monoclonal antibody. Pediatr. Nurs. 1999, 25, 527–530.
   PubMedGoogle Scholar
• Simmons, C.P., Bernasconi, N.L., Suguitan, A.L., et al. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 2007, 4, e178.
   PubMedGoogle Scholar
• ter Meulen, J., Bakker, A.B. van, den Brink, E.N. et, al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004, 363, 2139–2141.
   PubMed Web of Science ®Google Scholar
• Gigliotti, F., Haidaris, C.G., Wright, T.W., Harmsen, A.G. Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect. Immun. 2002, 70, 1069–1074.
   PubMed Web of Science ®Google Scholar
• Ferrantelli, F., Hofmann-Lehmann, R., Rasmussen, R.A., et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003, 17, 301–309.
   PubMed Web of Science ®Google Scholar
• Bailey, G.S. Antibody techniques. In Walker, J.M., ed. The Protein Protocols Handbook (pp. 969–970). New Jersey: Humana Press Inc., 2002.
   Google Scholar
• Bailey, G.S. Antibody techniques. In Walker, J.M., ed. The Protein Protocols Handbook (pp. 963–966). New Jersey: Humana Press Inc., 2002.
   Google Scholar
• Perk, L.R., Vosjan, M.J., Visser, G.W., et al. p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur. J. Nucl. Med. Mol. Imaging 2010, 37, 250–259.
   PubMedGoogle Scholar
• Singh, R., Erickson, H.K. Therapeutic Antibodies: Methods and Protocols. New Jersey: Humana Press Inc., 2009.
   Google Scholar
• Wong, S.S. Chemistry of Protein Conjugation and Cross-Linking. CRC Press LLC, Florida, USA. 1991.
   Google Scholar
• Ghetie, V., Vitetta, E.S. Chemical construction of immunotoxins. In Francis, G.E., Delgado, C., eds. Drug Targeting: Strategies, Principles, and Applications (Methods in Molecular Medicine) (pp. 1–26). New Jersey: Humana press Inc., 2000.
   Google Scholar
• Erwin, W.D., Esmaeli, B. Estimation of yttrium-90 Zevalin tumor-absorbed dose in ocular adnexal lymphoma using quantitative indium-111 Zevalin radionuclide imaging. Nucl. Med. Commun. 2009, 30, 681–686.
   PubMedGoogle Scholar
• Kumar, R.A., Ikemoto, N., Patel, D.J. Solution structure of the calicheamicin gamma 1I-DNA complex. J. Mol. Biol. 1997, 265, 187–201.
   PubMed Web of Science ®Google Scholar
• Singla, M. Antibody based target tailored antimicrobial chemotherapy—a new approach. Med. Hypotheses 2007, 68, 957–959.
   PubMedGoogle Scholar
• BL22 immunotoxin. http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=43322 (accessed November 20, 2009.).
   Google Scholar
• National Cancer Institute. Clinical Trials. BL22 immunotoxin. http://www.cancer.gov/search/ResultsClinicalTrials.aspx? protocolsearchid=6445617 (accessed November 28, 2009.).
   Google Scholar
• Kreitman, R.J. Immunotoxins for targeted cancer therapy. AAPS J. 2006, 8, E532–E551.
   PubMed Web of Science ®Google Scholar
• Kreitman, R.J., Wilson, W.H., Bergeron, K., et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 2001, 345, 241–247.
   PubMed Web of Science ®Google Scholar
• Lenz, H.J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007, 12, 601–609.
   PubMed Web of Science ®Google Scholar
• Kaminetzky, D., Hymes, K.B. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Biologics 2008, 2, 717–724.
   PubMedGoogle Scholar
• Minami, S., Ueda, R., Shiraki, T., et al. Two monoclonal antibodies detecting allotypic determinants of HLA-A. Tissue Antigens 1983, 22, 239–245.
   PubMedGoogle Scholar
• Wood, J.C.S., Horton, A.F., Byrne, J.D., Pedroso, R.I., Bisnow, M., Auer, R.E. Dual laser excitation flow cytometry: the state of the art. In Yen, A., ed., Flow Cytometry: Advanced Research and Clinical Applications (pp. 5–62). Florida: CRC Press, Inc., 1989.
   Google Scholar
• Plesa, C., Chelghoum, Y., Plesa, A., Elhamri, M., Tigaud, I., Michallet, M., Dumontet, C., Thomas, X.. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience. Cancer. 2008, 112, 572–580.
   PubMed Web of Science ®Google Scholar
• O’Gorman, M.R.G., Scholl, P.R. Role of flow cytometry in the diagnostic evaluation of primary immunodeficiency disease. Clin. Applied. Immunol. Rev. 2002, 2, 321–335.
   Google Scholar
• Regnault, V., Arvieux, J., Vallar, L., Lecompte, T. Immuno-purification of human beta2-glycorprotein I with a monoclonal antibody selected for its binding kinetics using a surface plasmon resonance biosensor. J. Immunol. Methods 1998, 211, 191–197.
   PubMedGoogle Scholar
• King, D.J. Monoclonal antibodies in research and diagnostic applications. In King, D.J., ed., Applications and Engineering of Monoclonal Antibodies (pp. 102–109). London & Pennsylvania: Taylor & Francis Ltd., 1998.
   Google Scholar
• Friedman, F.K., Robinson, R.C., Park, S.S., Gelboin, H.V. Monoclonal antibody-directed immunopurification and identification of cytochromes P-450. Biochem. Biophys. Res. Commun. 1983, 116, 859–865.
   PubMed Web of Science ®Google Scholar
• Kenney, A., Goulding, L., Hill, C. The design, preparation, and use of immunopurification reagents. In Walker, J.M., ed. New Protein Techniques (pp. 99–110). New Jersey: Humana Press, 1988.
   Google Scholar
• Jung, M., Kletter, K., Dudczak, R., et al. Deep vein thrombosis: scintigraphic diagnosis with In-111-labeled monoclonal antifibrin antibodies. Radiology 1989, 173, 469–475.
   PubMedGoogle Scholar
• Oyen, W.J., Witjes, J.A., Corstens, F.H. Nuclear medicine techniques for the diagnosis and therapy of prostate carcinoma. Eur. Urol. 2001, 40, 294–299.
   PubMedGoogle Scholar
• Taneja, S.S. ProstaScint(R) scan: contemporary use in clinical practice. Rev. Urol. 2004, 6(Suppl 10), S19–S28.
   PubMedGoogle Scholar